Literature DB >> 31818980

Borrelia miyamotoi Activates Human Dendritic Cells and Elicits T Cell Responses.

Lauren M K Mason1, Joris Koetsveld2, Jos J A Trentelman2, Tanja M Kaptein3, Dieuwertje Hoornstra2, Alex Wagemakers2, Michelle M Fikrig2, Jasmin I Ersoz2, Anneke Oei4, Teunis B H Geijtenbeek3, Joppe W R Hovius2,5.   

Abstract

The spirochete Borrelia miyamotoi has recently been shown to cause relapsing fever. Like the Lyme disease agent, Borrelia burgdorferi, B. miyamotoi is transmitted through the bite of infected ticks; however, little is known about the response of the immune system upon infection. Dendritic cells (DCs) play a central role in the early immune response against B. burgdorferi We investigated the response of DCs to two different strains of B. miyamotoi using in vitro and ex vivo models and compared this to the response elicited by B. burgdorferi. Our findings show that B. miyamotoi is phagocytosed by monocyte-derived DCs, causing upregulation of activation markers and production of proinflammatory cytokines in a similar manner to B. burgdorferi. Recognition of B. miyamotoi was demonstrated to be partially mediated by TLR2. DCs migrated out of human skin explants upon inoculation of the skin with B. miyamotoi. Finally, we showed that B. miyamotoi-stimulated DCs induced proliferation of naive CD4+ and CD8+ T cells to a larger extent than B. burgdorferi. In conclusion, we show in this study that DCs respond to and mount an immune response against B. miyamotoi that is similar to the response to B. burgdorferi and is able to induce T cell proliferation.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Year:  2019        PMID: 31818980     DOI: 10.4049/jimmunol.1801589

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  1 in total

1.  NKG2D Enhances Double-Negative T Cell Regulation of B Cells.

Authors:  Shi-Hua Hu; Long-Hui Zhang; Jie Gao; Jing-Heng Guo; Xiao-Dong Xun; Xiao Xiang; Qian Cheng; Zhao Li; Ji-Ye Zhu
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.